Plant Name: Lycopus europaeus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; GPBAR1; | |
| TSHR; | |
| RECQL; PLA2G1B; TDP1; PKM; GLO1; HSD11B1; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; ALOX12; AKR1B10; NOX4; USP2; TNKS; PARP1; TNKS2; APEX1; POLB; CD38; | |
| PTPRF; PTPN1; CDC25B; PTPN2; ACP1; | |
| ACHE; GAA; | |
| CFTR; | |
| CSNK2A1; SYK; FLT3; GSK3B; CDK6; | |
| CA12; CA3; CA14; CA5B; CA4; CA1; CA9; CA7; CA6; CA2; CA5A; | |
| AR; | |
| NR1H4; NR1H3; | |
| NR1I2; | |
| PPARA; PPARG; | |
| RORC; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; PTGS1; PTGS2; XDH; | |
| CASP7; CASP1; | |
| MMP12; MMP2; MMP9; MMP1; | |
| F2; | |
| HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; MCL1; MAPT; THPO; RAB9A; NPC1; APP; TTR; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 1 group H | NR1H3 | LXR-alpha | Q13133 | CHEMBL2808 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 6.195E-11 | 2.498E-08 | CA2, CA7, CFTR, F2, HIF1A, NPC1, NR1H3, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.175E-10 | 1.080E-07 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H3, NR1H4, RORC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 9.310E-10 | 2.855E-07 | CA2, CA7, CD38, CDK6, CFTR, F2, HIF1A, NPC1, NR1H3, NR1H4, PARP1, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.333E-09 | 1.037E-06 | CYP19A1, F2, FFAR4, NFKB1, NR1H3, NR1H4, PPARA, PPARG, PTPN2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.134E-09 | 1.164E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.116E-08 | 2.360E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP3A4, NOX4, PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.279E-08 | 2.678E-06 | AR, ESR1, ESR2, NR1H3, NR1H4, NR1I2, PPARA, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 4.708E-08 | 8.993E-06 | CASP1, CD38, CYP1A1, HIF1A, LMNA, MMP2, NOX4, PKM, PPARA, PTGS2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.292E-08 | 1.357E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.407E-08 | 1.367E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.777E-08 | 1.411E-05 | AR, ESR1, ESR2, NR1H3, NR1H4, NR1I2, PPARA, PPARG, RORC |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.281E-07 | 2.113E-05 | ABCG2, ACHE, APP, CASP1, CD38, CSNK2A1, ESR1, ESR2, FLT3, L3MBTL1, MAPT, MCL1, MMP9, NFKB1, PARP1, PKM, PPARG, PTGS2, RAB9A, SMN1, SMN2, TP53, TTR, USP2, XDH |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.393E-07 | 2.247E-05 | AR, CASP1, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1, NR1H3, NR1H4, PPARG, RORC |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.676E-07 | 2.644E-05 | AR, ESR1, ESR2, NR1H3, NR1H4, NR1I2, PPARA, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.420E-07 | 3.585E-05 | CYP1A2, CYP2A6, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 8.767E-07 | 1.116E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 2.138E-06 | 2.464E-04 | NR1H3, PPARA, PPARG |
| BP | GO:0009987; cellular process | GO:0060336; negative regulation of interferon-gamma-mediated signaling pathway | 2.138E-06 | 2.464E-04 | NR1H3, PPARG, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.830E-06 | 3.097E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.830E-06 | 3.097E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2A6 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 4.759E-06 | 4.912E-04 | F2, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 5.946E-06 | 6.022E-04 | HIF1A, MCL1, PARP1 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 7.802E-06 | 7.386E-04 | NR1H3, PPARA, PPARG, RORC, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 9.248E-06 | 8.461E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 1.008E-05 | 8.927E-04 | APP, CSNK2A1, CYP1B1, ESR1, GSK3B, MAPT, MMP9, NFKB1, NR1H4, PPARA, PPARG, PTGS2, PTPN1, PTPN2, PTPRF, RAB9A, TNKS, TP53 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 1.070E-05 | 9.436E-04 | AR, CA2, CD38, FLT3, NPC1, NR1H3, PARP1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 1.116E-05 | 9.643E-04 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B1 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.226E-05 | 1.051E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9, PLA2G1B |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.265E-05 | 1.072E-03 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.265E-05 | 1.072E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.265E-05 | 1.072E-03 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 1.294E-05 | 1.084E-03 | CYP19A1, NFKB1, NR1H3, PPARA, PPARG, SYK |
| BP | GO:0008152; metabolic process | GO:0045923; positive regulation of fatty acid metabolic process | 1.434E-05 | 1.183E-03 | NR1H3, PPARA, PPARG, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.734E-05 | 1.419E-03 | AR, CYP19A1, ESR1 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.023E-05 | 1.614E-03 | AKR1B1, ALOX5, APEX1, AR, CASP7, CDC25B, CDK6, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, L3MBTL1, LMNA, MCL1, NFKB1, NR1H3, NR1H4, NR1I2, PARP1, POLB, PPARA, PPARG, PTPN2, RECQL, RORC, SMN1, SMN2, TNKS, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0000122; negative regulation of transcription from RNA polymerase II promoter | 2.281E-05 | 1.765E-03 | AR, ESR1, ESR2, MMP12, NFKB1, NR1H3, NR1H4, PARP1, PPARA, PPARG, PTPN2, RORC, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.293E-05 | 1.765E-03 | APEX1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.293E-05 | 1.765E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.293E-05 | 1.765E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.293E-05 | 1.765E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.293E-05 | 1.765E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.692E-05 | 2.043E-03 | MMP1, MMP12, MMP2, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0010745; negative regulation of macrophage derived foam cell differentiation | 2.984E-05 | 2.241E-03 | NR1H3, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0006694; steroid biosynthetic process | 3.277E-05 | 2.435E-03 | AKR1B1, CFTR, CYP19A1, CYP3A4, HSD11B1, HSD17B1 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 3.435E-05 | 2.536E-03 | ALOX15, APP, AR, FFAR4, FLT3, NOX4, PLA2G1B, PTPN1, SYK, THPO, XDH |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 3.488E-05 | 2.558E-03 | GSK3B, MAPT, MCL1, PARP1, TP53 |
| BP | Unclassified; | GO:2000188; regulation of cholesterol homeostasis | 3.785E-05 | 2.728E-03 | NPC1, NR1H3, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 4.727E-05 | 3.316E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
| MF | GO:0005488; binding | GO:0000977; RNA polymerase II regulatory region sequence-specific DNA binding | 4.800E-05 | 3.328E-03 | AR, ESR1, ESR2, HIF1A, NFKB1, NR1H3, NR1H4, NR1I2, PARP1, PPARA, RORC, TP53 |
| BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 5.319E-05 | 3.620E-03 | ALOX15, APP, FFAR4, NOX4, PTPN1, PTPN2, SYK, THPO |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 5.930E-05 | 3.957E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, CFTR, ESR1, F2, HIF1A, PLA2G1B, TP53 |
| BP | GO:0008283; cell proliferation | GO:0048145; regulation of fibroblast proliferation | 5.943E-05 | 3.957E-03 | CDK6, ESR1, PLA2G1B, PPARG, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 5.943E-05 | 3.957E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 5.898E-05 | 3.957E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 6.003E-05 | 3.985E-03 | ACP1, AKR1B1, AKR1B10, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, CA1, CA2, CA3, CA7, CASP1, CASP7, CDC25B, CDK6, CFTR, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, LMNA, MAPT, MCL1, NFKB1, PKM, PLA2G1B, PPARG, PTPN1, PTPN2, RAB9A, SMN1, SMN2, SYK, TNKS, TNKS2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 6.509E-05 | 4.295E-03 | AKR1B1, APEX1, CDK6, CFTR, CYP1B1, NFKB1, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.858E-05 | 4.392E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.858E-05 | 4.392E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 6.858E-05 | 4.392E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.858E-05 | 4.392E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 6.858E-05 | 4.392E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 6.858E-05 | 4.392E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.858E-05 | 4.392E-03 | GPBAR1, NR1H4 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 7.042E-05 | 4.484E-03 | ALOX12, APP, CD38, CDK6, F2, FFAR4, GSK3B, HIF1A, LMNA, NFKB1, NR1H3, NR1H4, PPARG, PTGS2, PTPN2, XDH |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 7.287E-05 | 4.599E-03 | ACHE, APEX1, CSNK2A1, FLT3, L3MBTL1, MAPT, MMP12, MMP9, PKM, PPARA, PTPN1, PTPN2, PTPRF, SYK, TSHR |
| BP | GO:0009987; cellular process | GO:0071248; cellular response to metal ion | 8.053E-05 | 5.010E-03 | ALOX15, CYP1A1, CYP1A2, MMP9, PARP1, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 8.745E-05 | 5.395E-03 | ABCG2, APP, CA2, CA7, CD38, CFTR, ESR1, F2, HIF1A, PLA2G1B, TP53 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 9.557E-05 | 5.829E-03 | HIF1A, MCL1, MMP9, PTGS2, PTPN1 |
| BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 9.788E-05 | 5.937E-03 | APEX1, APP, CFTR, NOX4 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.074E-04 | 6.461E-03 | ALOX15, ESR1, GSK3B, MAPT, MMP1, PARP1, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0051240; positive regulation of multicellular organismal process | 1.133E-04 | 6.761E-03 | ALOX12, APP, AR, CA2, CASP1, CD38, CYP1B1, F2, HIF1A, MAPT, MMP12, MMP9, NFKB1, NR1H4, PARP1, PPARG, PTGS2, SYK, THPO |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.162E-04 | 6.876E-03 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.195E-04 | 7.016E-03 | FFAR1, HIF1A, NOX4, NR1H4, PPARG, PTPN2 |
| MF | GO:0005488; binding | GO:0019904; protein domain specific binding | 1.239E-04 | 7.192E-03 | APP, AR, CASP1, CFTR, HIF1A, L3MBTL1, MAPT, MCL1, PPARA, PPARG, SYK, TP53 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.301E-04 | 7.527E-03 | APEX1, CA5A, CA5B, CASP1, CYP1A1, CYP1B1, ESR2, GSK3B, HSD17B10, MAOA, MCL1, MMP2, NFKB1, NOX4, PARP1, PKM, TP53 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.325E-04 | 7.570E-03 | NOX4, PARP1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0043621; protein self-association | 1.325E-04 | 7.570E-03 | ACHE, FLT3, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.367E-04 | 7.615E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.367E-04 | 7.615E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.367E-04 | 7.615E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.367E-04 | 7.615E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.367E-04 | 7.615E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.367E-04 | 7.615E-03 | ALDH1A1, AR |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 1.416E-04 | 7.807E-03 | MAPT, PPARA, PPARG, PTPN1, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:2000278; regulation of DNA biosynthetic process | 1.534E-04 | 8.332E-03 | NOX4, PPARG, TNKS, TNKS2, TP53 |
| MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 1.569E-04 | 8.479E-03 | AR, ESR1, HIF1A, NFKB1, NR1H4, NR1I2, PARP1, PPARA, TP53 |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 1.729E-04 | 9.181E-03 | APP, AR, ESR1, ESR2, NFKB1, PLA2G1B, PPARG |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.750E-04 | 9.232E-03 | AKR1B1, APEX1, CYP1B1, MMP9, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.750E-04 | 9.232E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.784E-04 | 9.385E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0010803; regulation of tumor necrosis factor-mediated signaling pathway | 1.872E-04 | 9.749E-03 | CASP1, NR1H4, PTPN2, SYK |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.348E-23 | 2.557E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.382E-18 | 6.021E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.162E-18 | 2.236E-14 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, L3MBTL1, MMP1, MMP12, MMP2, MMP9, NR1H3, NR1H4, NR1I2, PARP1, PPARA, PPARG, PTPN1, RORC, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.331E-16 | 1.451E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.442E-22 | 2.480E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.853E-08 | 2.209E-06 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PTGS2; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD11B1; CYP2A6; PKM; AKR1B10; HSD17B1; ALOX5; CYP1A2; ALDH1A1; CYP1A1; CD38; XDH |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.264E-09 | 7.967E-07 | HSD11B1; HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.105E-07 | 8.900E-06 | AR; GSK3B; CDK6; FLT3; MMP1; MMP2; PPARG; PTGS2; HIF1A; TP53; MMP9; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.157E-07 | 3.980E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.280E-07 | 1.052E-05 | PLA2G1B; ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.070E-07 | 3.980E-06 | HSD11B1; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.108E-07 | 1.848E-05 | APP; MAOA; ALOX5; ALOX15; ALOX12; PTGS2; PTGS1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.138E-06 | 1.957E-05 | HSD11B1; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.005E-05 | 1.440E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MMP9; NFKB1; CDC25B; MCL1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.183E-05 | 1.566E-04 | PTPN1; GSK3B; NR1H3; PPARA; NFKB1; PTPRF |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.292E-05 | 1.588E-04 | CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.886E-05 | 4.423E-04 | CASP7; PARP1; LMNA; TP53; NFKB1; MCL1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.154E-05 | 3.969E-04 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.993E-05 | 2.285E-04 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 9.518E-06 | 1.440E-04 | PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.522E-05 | 3.786E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 7.341E-05 | 6.313E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.889E-05 | 3.935E-04 | MMP1; MMP2; MMP9; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.622E-04 | 2.331E-03 | GSK3B; SYK; CSNK2A1; CD38; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.917E-04 | 2.331E-03 | POLB; CDK6; PKM; SYK; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.684E-04 | 2.198E-03 | PKM; FLT3; TP53; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.539E-04 | 2.331E-03 | GSK3B; ESR1; NFKB1; ESR2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.923E-04 | 2.331E-03 | GSK3B; NR1H3; PPARA; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.006E-04 | 2.248E-03 | CYP2A6; MAOA; CYP1A2; CYP3A4 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.996E-04 | 3.760E-03 | GSK3B; CASP7; NR1H3; PPARA; NFKB1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.006E-04 | 2.248E-03 | MMP1; NR1H3; PPARG; PPARA |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.931E-04 | 2.331E-03 | PTPN1; CSNK2A1; ACP1; PTPRF |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 7.910E-04 | 4.123E-03 | GSK3B; AR; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.953E-04 | 3.760E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.129E-03 | 5.393E-03 | APP; GSK3B; CASP7; MAPT; HSD17B10 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.177E-03 | 5.473E-03 | MMP2; ESR1; MMP9; ESR2 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.050E-03 | 5.311E-03 | CA2; PLA2G1B; CD38; CFTR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.532E-03 | 6.757E-03 | FLT3; PPARG; TP53; MMP9; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.737E-03 | 7.468E-03 | CASP7; PTGS2; MMP9; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.588E-03 | 1.012E-02 | MMP2; TP53; HIF1A; ESR1; MMP9 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.244E-03 | 9.030E-03 | GSK3B; TP53; ESR1; HIF1A |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.173E-03 | 1.711E-02 | GSK3B; CDK6; SYK; TP53; NFKB1; MCL1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.815E-03 | 1.690E-02 | CDK6; TP53; MMP9; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.686E-03 | 1.027E-02 | GSK3B; CDK6; TP53; CDC25B |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.786E-03 | 1.690E-02 | CDK6; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.786E-03 | 1.690E-02 | GSK3B; SYK; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.396E-02 | 4.140E-02 | PPARA; CFTR; NFKB1; TSHR |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.608E-04 | 2.331E-03 | AKR1B10; GAA; AKR1B1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.604E-03 | 1.348E-02 | CDK6; TP53; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.258E-03 | 9.030E-03 | PTGS2; TSHR; PTGS1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 9.618E-03 | 2.976E-02 | PPARG; TP53; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.144E-03 | 8.993E-03 | CASP7; CASP1; NFKB1 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 8.032E-03 | 2.558E-02 | THPO; FLT3; CD38 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.161E-03 | 1.711E-02 | CASP7; CASP1; NFKB1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.123E-03 | 5.393E-03 | ABCC1; CFTR; ABCG2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.278E-03 | 5.786E-03 | CYP2A6; CYP3A4; XDH |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.800E-04 | 2.752E-03 | POLB; PARP1; APEX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.668E-07 | 1.848E-05 | CYP2A6; CYP1A2; XDH |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.004E-03 | 2.558E-02 | PPARG; TP53 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 1.488E-02 | 4.337E-02 | PKM; GLO1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.216E-02 | 3.670E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 9.690E-03 | 2.976E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.079E-03 | 1.711E-02 | CA2; CA4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; F2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PKM; SYK; FLT3; CA9; MMP2; F2; HIF1A; MMP9; TP53 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; NR1I2; ALOX5; MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2; MMP1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; MMP9; TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; CYP3A4 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F2 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ALOX5; SYK; CASP1; PTGS2; PTGS2; PTGS2; PTGS2; MMP1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F2 |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; PPARG; PPARG; APP |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; FFAR1; PTGS2; NFKB1; PPARG; PPARG; GPBAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; CD38; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F2 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; ESR1; ESR1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; MCL1; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; F2; CD38; GSK3B; HIF1A; MMP9; NFKB1; PARP1; CDC25B; TP53; ESR1; ESR1; APP |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; ALOX5; SYK; MMP12; PTGS1; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; F2 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2; PPARG |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; PTGS1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | F2; ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; PTPN1; FFAR1; GSK3B; PPARG |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; F2; F2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MMP12; MMP12 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; F2; PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |